» Authors » Yvette van Norden

Yvette van Norden

Explore the profile of Yvette van Norden including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 613
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Verduijn G, Capala M, Sijtsema N, Lauwers I, Hernandez Tamames J, Heemsbergen W, et al.
BMJ Open . 2022 May; 12(5):e059345. PMID: 35584883
Introduction: The locoregional failure (LRF) rate in human papilloma virus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) remains disappointingly high and toxicity is substantial. Response prediction prior to or early during...
12.
Baak R, Willemssen F, van Norden Y, Eskens F, Milder M, Heijmen B, et al.
Cancers (Basel) . 2021 Aug; 13(16). PMID: 34439146
Background: In unresectable pCCA, the standard of care is palliative chemotherapy. We investigated the feasibility and safety of adding stereotactic body radiation therapy (SBRT) after chemotherapy. Methods: Patients with unresectable...
13.
Janssen J, Lowenberg B, Manz M, Bargetzi M, Biemond B, Borne P, et al.
Cancers (Basel) . 2021 Feb; 13(4). PMID: 33562393
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a...
14.
Kalin B, van Norden Y, van Gelder M, Breems D, Maertens J, Jongen-Lavrencic M, et al.
Blood Adv . 2020 Sep; 4(18):4430-4437. PMID: 32936907
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect more effectively, we assessed the feasibility of early...
15.
Rick T, Habtamu B, Tigeneh W, Abreha A, van Norden Y, Grover S, et al.
J Glob Oncol . 2019 Dec; 5:1-8. PMID: 31834831
Purpose: Radiotherapy (RT) is an essential component of cancer treatment. There is a lack of RT services in sub-Saharan Africa as well as limited knowledge regarding clinical practices. The purpose...
16.
Kater A, Kersting S, van Norden Y, Dubois J, Dobber J, Mellink C, et al.
Blood Adv . 2018 Dec; 2(24):3566-3571. PMID: 30552161
Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS)....
17.
Kater A, van Oers M, van Norden Y, van der Straten L, Driessen J, Posthuma W, et al.
Haematologica . 2018 Aug; 104(1):147-154. PMID: 30115656
Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this...
18.
van Rosmalen J, Dejardin D, van Norden Y, Lowenberg B, Lesaffre E
Stat Methods Med Res . 2017 Mar; 27(10):3167-3182. PMID: 28322129
Data of previous trials with a similar setting are often available in the analysis of clinical trials. Several Bayesian methods have been proposed for including historical data as prior information...
19.
Lowenberg B, Pabst T, Maertens J, van Norden Y, Biemond B, Schouten H, et al.
Blood . 2017 Jan; 129(12):1636-1645. PMID: 28049642
Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be critically evaluated in younger adults in the frontline with standard chemotherapy. We compared 2 induction...
20.
Libourel E, Klerk C, van Norden Y, de Maat M, Kruip M, Sonneveld P, et al.
Blood . 2016 Jun; 128(14):1854-1861. PMID: 27354723
Venous thromboembolism is a common complication in patients with cancer, but only limited data are available in acute myeloid leukemia (AML). In a prospective study in a cohort of 272...